|
Although it was only licensed for the treatment of
bone spavin in the UK in February 2008, Tildren®
has in fact been used in Europe for several years
as an aid in the management of chronic performance-limiting
diseases such as bone spavin and navicular disease.
Administered as a single infusion over a period of
30-40 minutes, the drug has the advantage of being
straightforward to use and can be given in practice
or at the horse’s yard, depending on the patient
and the owner’s requirements.
When 15-year-old Mia, an FEI event pony who had been
previously short-listed for the British team, was
diagnosed with bilateral degenerative joint disease
(DJD) in both hocks her owner, Helen Walsh from High
Wycombe in Buckinghamshire, thought the talented pony’s
career at this testing level was probably over. However,
Mia was treated with Tildren® in combination with
corticosteroids and six months later the mare, who
is by Welton Apollo, was back on the FEI event circuit
with Helen’s fifteen-year-old daughter Elsa.
Mia’s groom Ellen Murphy said: “Mia has
already done two events this season and is going superbly.
She’s not even stiff the day after an event
which is amazing considering her age. This will be
her last year competing at FEI level as Elsa will
be moving on to horses but at this rate Mia still
has plenty of energy and enthusiasm for a slightly
easier life as a Pony Club pony next year.”
In horses suffering from bone spavin there are important
bone remodelling changes, with excessive bone resorption
in the tarsal bones. Tildren® works by regulating
this bone remodelling through a decrease in the resorptive
process. By orientating bone metabolism towards a
normalisation of bone remodelling, Tildren® is
designed to slow down the degradation of the bone
structure in the hock when the condition is progressing
and to alleviate pain associated with abnormal bone
lysis. The product has proven efficacy in UK trials
and safety with multiple doses.
CEVA has recently produced a leaflet specifically
to help horse owners to understand the diagnosis and
treatment of bone spavin. For copies of this leaflet
and CEVA’s comprehensive veterinary brochure
on the product please contact CEVA Animal Health on
01494 781510 or visit the website at www.tildren.com
|
